Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 14 | 2023 | 369 | 5.600 |
Why?
|
| Mastectomy | 7 | 2023 | 35 | 1.610 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2019 | 18 | 1.240 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 154 | 1.060 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2022 | 3 | 0.830 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2022 | 11 | 0.820 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 14 | 0.790 |
Why?
|
| Mammaplasty | 1 | 2021 | 7 | 0.760 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 351 | 0.760 |
Why?
|
| Carcinoma, Ductal | 1 | 2019 | 3 | 0.640 |
Why?
|
| Hypercalcemia | 1 | 2019 | 11 | 0.640 |
Why?
|
| Breast Neoplasms, Male | 1 | 2019 | 10 | 0.640 |
Why?
|
| Female | 15 | 2023 | 14273 | 0.630 |
Why?
|
| Referral and Consultation | 2 | 2021 | 86 | 0.630 |
Why?
|
| Tamoxifen | 1 | 2019 | 26 | 0.630 |
Why?
|
| Stromal Cells | 1 | 2018 | 28 | 0.610 |
Why?
|
| Hemangiosarcoma | 1 | 2017 | 8 | 0.580 |
Why?
|
| Retrospective Studies | 8 | 2023 | 3220 | 0.580 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 107 | 0.560 |
Why?
|
| Patient Compliance | 1 | 2018 | 148 | 0.560 |
Why?
|
| Humans | 17 | 2023 | 25692 | 0.540 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2016 | 4 | 0.540 |
Why?
|
| Mastectomy, Segmental | 1 | 2016 | 30 | 0.530 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 26 | 0.530 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 32 | 0.530 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 284 | 0.530 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 70 | 0.510 |
Why?
|
| Carcinoma, Lobular | 1 | 2015 | 19 | 0.480 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2015 | 32 | 0.470 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 163 | 0.450 |
Why?
|
| Disease Management | 1 | 2015 | 97 | 0.450 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 315 | 0.430 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 4459 | 0.420 |
Why?
|
| Decision Making | 1 | 2015 | 203 | 0.410 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 66 | 0.410 |
Why?
|
| Aged | 6 | 2023 | 8501 | 0.410 |
Why?
|
| Postoperative Complications | 1 | 2016 | 827 | 0.350 |
Why?
|
| Case-Control Studies | 2 | 2023 | 532 | 0.320 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2008 | 1 | 0.300 |
Why?
|
| Quality of Life | 2 | 2022 | 600 | 0.280 |
Why?
|
| Adult | 5 | 2022 | 7336 | 0.230 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2023 | 14 | 0.210 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 90 | 0.200 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2019 | 19 | 0.200 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 1689 | 0.190 |
Why?
|
| Mutation | 1 | 2023 | 325 | 0.190 |
Why?
|
| Length of Stay | 1 | 2023 | 300 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 69 | 0.170 |
Why?
|
| Acellular Dermis | 1 | 2019 | 7 | 0.160 |
Why?
|
| Breast Implantation | 1 | 2019 | 4 | 0.160 |
Why?
|
| Breast Implants | 1 | 2019 | 7 | 0.160 |
Why?
|
| Treatment Outcome | 2 | 2019 | 3231 | 0.160 |
Why?
|
| Middle Aged | 3 | 2023 | 8403 | 0.160 |
Why?
|
| Mammography | 1 | 2019 | 41 | 0.160 |
Why?
|
| Time Factors | 3 | 2019 | 1336 | 0.150 |
Why?
|
| Needles | 1 | 2016 | 12 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2016 | 51 | 0.130 |
Why?
|
| Age Factors | 1 | 2018 | 716 | 0.130 |
Why?
|
| Biopsy | 1 | 2015 | 199 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 333 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 1084 | 0.110 |
Why?
|
| Prognosis | 1 | 2015 | 739 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 698 | 0.090 |
Why?
|
| Young Adult | 1 | 2016 | 1855 | 0.090 |
Why?
|
| Amenorrhea | 1 | 2009 | 1 | 0.080 |
Why?
|
| Oocytes | 1 | 2009 | 5 | 0.080 |
Why?
|
| Embryo, Mammalian | 1 | 2009 | 22 | 0.080 |
Why?
|
| Cryopreservation | 1 | 2009 | 13 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 169 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2008 | 235 | 0.060 |
Why?
|
| Male | 1 | 2019 | 13917 | 0.050 |
Why?
|
| Adolescent | 1 | 2008 | 2076 | 0.050 |
Why?
|
| Radiologists | 1 | 2019 | 5 | 0.040 |
Why?
|
| Esthetics | 1 | 2019 | 12 | 0.040 |
Why?
|
| Pectoralis Muscles | 1 | 2019 | 13 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2019 | 20 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2019 | 43 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 83 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 124 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2019 | 123 | 0.040 |
Why?
|
| Wound Healing | 1 | 2019 | 150 | 0.040 |
Why?
|
| Surgeons | 1 | 2019 | 86 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 217 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 392 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 329 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2019 | 618 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2019 | 475 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 1781 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 59 | 0.020 |
Why?
|